Picture EBD Group Global Partnering Four Events One Price 650x80
Organisation › Details

Leyden Laboratories B.V. (Leyden Labs)

Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. *


Period Start 2021-03-25 existent
Products Industry virostatic agent
  Industry 2 drug development
Region Region Amsterdam
  Country Netherlands
  Street 290 A Keizersgracht
  City 1016 EW Amsterdam
    Address record changed: 2021-04-07
Basic data Employees n. a.
    * Document for �About Section�: Leyden Laboratories B.V.. (3/25/21). "Press Release: Leyden Labs to Unlock a New Generation of Preventative Medicines against Known and Future Viruses by Securing a €40 Million Series A from GV (formerly Google Ventures), F-Prime and Casdin Capital". Ams
Record changed: 2021-04-07


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Leyden Laboratories B.V. (Leyden Labs)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top